z-logo
open-access-imgOpen Access
Encorafenib in combination with binimetinib — a new therapeutic option with a favourable safety profile in the treatment of patients with advanced BRAF mutation-positive melanoma
Author(s) -
Paulina Jagodzińska-Mucha,
Piotr Rutkowski
Publication year - 2020
Publication title -
oncology in clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 2
eISSN - 2450-6478
pISSN - 2450-1654
DOI - 10.5603/ocp.2019.0038
Subject(s) - medicine , safety profile , melanoma , mutation , oncology , dermatology , intensive care medicine , adverse effect , cancer research , genetics , biology , gene

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here